By Chris Wack


Argenx shares were up 25% to $474.87 in premarket trading after the company said it and Zai Lab saw positive topline results from their study evaluating Vyvgart Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic inflammatory demyelinating polyneuropathy.

Zai Lab shares were up 10% to $30.49 in premarket trading.

The companies said the study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared with placebo.

The study showed that the safety and tolerability profile was consistent with confirmed safety profile of Vyvgart, and 91% of eligible patients continued to the next phase of the open-label extension study.

The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All injection site reactions were mild to moderate and resolved over time.


Write to Chris Wack at


(END) Dow Jones Newswires

July 17, 2023 06:55 ET (10:55 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 argenx 차트를 더 보려면 여기를 클릭.
argenx (NASDAQ:ARGX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 argenx 차트를 더 보려면 여기를 클릭.